BIO 2002 Exhibitor Profiles; Exhibitor News Available at www.tradeshownews.com.

Business Editors/Biotechnology Writers

BIOWIRE2K

BIO 2002

TORONTO--(BW HealthWire)--June 7, 2002

BIO 2002 starts June 9 and runs through June 12. Listed below are profiles from BIO 2002 exhibitors. Exhibitor news releases and advisories are available at http://www.tradeshownews.com.

Company: ALZA
Booth: 635
Media Contact: Kathy Kim
Investor Relations Contact: Helen Short
Phone: [phone]
E-mail: [e-mail]
Company URL: www.alza.com

   ALZA Corporation, headquartered in Mountain View, California, is
the leading provider of drug delivery solutions with the world's
broadest array of technology platforms, including oral, transdermal,
implantable and liposomal technologies. ALZA partners with
pharmaceutical and biotechnology companies to develop and manufacture
pharmaceutical products that enhance health care for millions of
patients worldwide. More than 30 products marketed in over 80
countries incorporate ALZA's technologies and more than 3,000 US and
foreign patents are active or pending. ALZA Corporation is a member of
the Johnson & Johnson (NYSE:JNJ) family of companies.

Company: AnorMED Inc.
Booth: 1709
Media Contact:  Elisabeth Whiting
Investor Relations Contact: Elisabeth Whiting
Phone: [phone]
E-mail: [e-mail]
Company URL:  www.anormed.com
Press Kit URL: http://www.anormed.com/news/mediakit.html

Product description:
   AnorMED's late stage clinical products include: Fosrenol, which is
on track for a European market approval by mid-year 2002; AMD-473, an
anti-cancer agent in ongoing Phase II trials; AMD-3100, a potential
new agent for stem cell transplant in cancer patients, currently in a
Phase I trial; and Apomate, a prognostic imaging agent for cancer and
other diseases in Phase I/II trials. The Company is also focused on a
novel class of compounds that target specific receptors known to be
involved in HIV, rheumatoid arthritis, asthma and cancer.

Company description:
   AnorMED is focused on the discovery and development of small
molecule therapeutics for the treatment of diseases including
inflammation, cancer and HIV. AnorMED continues to build upon its drug
discovery and clinical development capabilities to support the rapid
advancement of its most promising therapeutic candidates into clinical
trials and to attract corporate partners

Company:  Battelle Healthcare Products
Booth:  2530-2532
Media Contact:  Gary L. Smith
Phone:  [phone]
E-mail:  [e-mail]
Company URL:  www.healthcare.battelle.org

Product Description:
   Battelle Healthcare Products provides leading edge technology and
comprehensive healthcare product development. We work from discovery
to development to commercialization and offer research & development,
industrial design, rapid prototyping, engineering, project management,
and pilot manufacturing. Battelle creates marketable solutions and new
products for diagnostic, therapeutic, drug delivery, cell therapy,
medical device and instrument companies around the world.

Company Description:
   Headquartered in Columbus, Ohio, Battelle serves industrial and
government customers in over 30 countries. Major innovations have
included the development of the office copier machine (XEROX),
pioneering work on the compact disc, medical product breakthroughs,
and advanced fiber optics for improved telecommunications. Battelle
Healthcare Products provides solutions for established and emerging
companies in the medical industry.

Company:  Biogen, Inc.
Booth: 1309
Media Contact: Gregory Peterson
Investor Relations Contact: Elizabeth Woo
Phone:  [phone]
E-mail: [e-mail]
Company URL: www.biogen.com
Press Kit URL: www.biogen.com/site/content/news_press.asp

Product Description:
   Biogen sells AVONEX(R) (Interferon beta-1a) to treat multiple
sclerosis. AMEVIVE(TM) (alefacept), to treat moderate-to-severe
chronic plaque psoriasis, is under U.S. and European regulatory
review. Worldwide sales by licensees of products including alpha
interferon, and hepatitis B vaccines and diagnostics also contribute
to Biogen's total revenue of over $1B in 2001.

Company Description:
   The world's oldest independent biotechnology company, Biogen has
global strength in research, development, manufacturing and marketing.
Headquartered in Cambridge, Massachusetts, Biogen's research and
development focuses on inflammation/autoimmunity, neurodegeneration,
cancer, fibrosis and congestive heart failure. The Company maintains
active clinical research programs in protein therapeutics, small
molecules and gene therapy.

Company: BioScience Park Lelystad
Booth: 128
Phone: [phone]
E-mail: [e-mail]
Company URL: www.biosciencepark.com

Product description:
   BioScience Park Lelystad offers excellent laboratory and office
accommodation to rent and building plots for your own business
premises. It is strategically situated in the center of the
Netherlands just a "stone's throw" from Lelystad Airport and Amsterdam
Airport Schiphol (one of the most important international airports in
the world).

Company description:
   BioScience Park Lelystad is designed for internationally renowned
pharmaceutical industries and affiliated companies and agribusiness.
In the hart of it all, there is an incubator for new start-ups.
Adjacent to the Institute for Animal Science and Health, ID-Lelystad,
offering unique experimental animal facilities and contract
manufacture of vaccines and diagnostics.

Company: BioValley Alsace
Booth: 2247 (French pavilion)
Media and Investor Relations Contact:  Sylvie SCHOTT
Phone: + 33 (0)3 90 40 30 00
E-mail: [e-mail]
Company URL: www.alsace-biovalley.com and www.biovalley.com

Product description:
   All year around, Alsace BioValley organises seminars, welcomes
International biotech delegations, publishes an electronic newsletter
and represents BioValley at trade fairs. Alsace BioValley is
distinguishing itself by its support to entrepreneurs. Thus, over the
last five years, more than 120 companies have been developed or
established within BioValley.

Company description:
   BioValley brings together all actors involved in the biotech
sector within the trinational region of the Upper Rhine Valley, which
includes Alsace in France, Bade-Wurtemberg in Germany and North-West
Switzerland. BioValley counts over 400 partners, representing more
than 2,000 people based in the three countries.

Company: Discovery Partners International, Inc.
Booth: 2321
Media Contact: Chris Herd
Investor Relations Contact: Craig Kussman
Phone: [phone]
E-mail: [e-mail]
Company URL: www.discoverypartners.com

Company description:
   Discovery Partners International, Inc. is a leader in
collaborative drug discovery. DPI offers integrated services and
products that span the drug discovery continuum including structure
and ligand based design, high throughput screening, combinatorial
chemistry, medicinal chemistry, and high throughput synthesis
automation. DPII is headquartered in San Diego, California and has
operations in the United States and Europe.

Company:     Diversa Corporation
Booth:      1739
Media Contact:    Virginia Amann or Michael Kulwiec (On site)
Phone:  [phone] or  858-526-5107
E-mail:  [e-mail]
Investor Relations Contact:   Hillary Theakston
Phone:      [phone]
E-mail:      [e-mail]
Company URL:    www.diversa.com

   Diversa Corporation is a leader in applying proprietary genomic
technologies for the rapid discovery and optimization of novel
products from genes and gene pathways. Diversa is directing its
integrated portfolio of technologies to the discovery, evolution, and
production of commercially valuable molecules with pharmaceutical
applications, such as optimized monoclonal antibodies and orally
active drugs, as well as enzymes and small molecules with
agricultural, chemical, and industrial applications.

Company:  Fish & Richardson P.C.
Booth:  1530
Media Contact:  Kelly Largey
Investor Relations Contact:  Kelly Largey
Phone:  [phone]
E-mail:  [e-mail]
Company URL:  www.fr.com

Product description:
   Company description: Fish & Richardson is one of the largest
intellectual property and technology law firms in the US, with 250
lawyers in eight offices. Our Biotechnology and Chemistry Group
includes 73 professionals, 41 who have Ph.D.'s. The group provides
patent services, handles patent infringement litigation, and provides
FDA advice. Our corporate attorneys assist biotechnology clients with
a wide variety of business transactions.

Company: GenVec, Inc.
Booth: 1121
Media Contact: Mary P. Sundeen
Investor Relations Contact: Mary P. Sundeen
Phone: [phone] or 240-372-7194 (cellular)
E-mail: [e-mail]
Company URL: www.genvec.com

Product Description:
   Our product candidates BioBypass, TNFerade and AdPEDF use
adenovectors to deliver therapeutic genes to diseased tissues via
standard medical devices such as syringes or injection catheters. This
increases effectiveness by producing therapeutic proteins where they
are needed and reduces toxicity by avoiding systemic exposure.

Company Description:
   GenVec is a publicly-held biotechnology company developing
gene-based therapies that produce medically beneficial proteins at the
site of disease. GenVec's product candidates include BioBypass for
heart disease, TNFerade for solid tumors, and AdPEDF to prevent
blindness. GenVec has 300+ patents protecting its proprietary genes
and gene transfer technologies.

Company: GTC Biotherapeutics, Inc.
Booth: 1535
Media Contact: Kathy Jones
Investor Contact: Tom Newberry
Phone:  [phone] or 508-620-9700
E-mail: [e-mail]
Company URL: www.gtc-bio.com

Product Description:
   GTC's technology and operating platform has the capability to
economically develop large volume proteins and enable development of
certain complex proteins that are impractical at commercial scale
using traditional bioreactor based systems. The flexibility and small
incremental investment of breeding additional animals from a
transgenic founder to generate a herd which produces the appropriate
production volumes is a key concept behind the favorable economics of
our platform. This can be particularly attractive for protein
therapeutics that may have a rapidly expanding market demand after
their initial commercial launch. We have also
   demonstrated our capabilities and have begun commercial
development of therapeutic blood proteins and certain immunoglobulin
fusion proteins that have been difficult to express using traditional
systems.

Company Description:
   GTC Biotherapeutics (GTC) (NASDAQ:GTCB) is a leader in the
production of therapeutic proteins in the milk of transgenic animals.
More than half of the transgenic proteins actively under development
by GTC are monoclonal antibodies (MAbs) or immunoglobulin (Ig) fusion
proteins. Our technology offers substantial economic and technological
advantages in comparison to traditional protein production systems,
including:

--Innovative solutions for large volume and difficult to express
protein therapeutics

--Higher production capability at lower operating and capital costs
for our partners

--Predictable and flexible expansion

Company: LMD PHARMACOGNOSIE
Booth: Hall D, French pavilion, BIOMAC booth No 2140
Media Contact: Antoine PELLET
Investor Relations Contact: Francois MICELI
Phone: + 33 (0) 4 73 39 62 40
E-mail: [e-mail]
Company URL: www.lmdpharma.com
Press Kit URL: www.lmdpharma.com/page_news.html

Product description:
   Since July 1999 date of its incorporation, LMD has 12 projects
with some into phase I and phase II clinical trials for the following
areas:

-- Infectious diseases
-- Alopecia
-- Skin bleaching
-- Dry eye syndrome
-- Libido stimulation
-- Estrogen like
-- Mild depression
-- Sun care
-- Pressure sores and wound healing
-- Metabolic disorder
-- Stretch marks

Company description:
LMD's mission: to discover, develop, patent and out license innovative
molecules used in pharmaceutical, cosmeceutical and nutraceutical from
its integrated ethno-pharmacological concept.  Advantages: unique and
original approach in integrating in house state-of-the-art
technologies leading to a fast drug discovery process.

Company: Neurochem Inc.
Booth: 2010
Media Contact: Dr. Lise Hebert
Investor Relations Contact: Dr. Lise Hebert
Phone: [phone]
E-mail: [e-mail]
Company URL: http://www.neurochem.com
Press Kit URL: http://www.neurochem.com/NewsRoom.htm

   Product description:
   Alzhemed(TM); Phase I; Alzheimer's Disease; initiate Phase II in
2002 Fibrillex(TM); pivotal Phase II/III; Secondary Amyloidosis;
ongoing Cerebril(TM); Phase I; Hemorrhagic Stroke due to CAA; initiate
Phase II in 2002 Lead compounds; preclinical; amyloid-associated Type
II Diabetes; out-license/partner Lead compounds; preclinical; Epilepsy
caused by head trauma or ACI; complete preclinical

Company description:
   Neurochem is an industry leader in the development of therapeutic
drugs and diagnostic tools for central nervous system and
amyloid-related diseases associated with aging, including Alzheimer's
Disease.

Company: Norgen Biotek Corp.
Booth: 1518
Media Contact: M. J. Al-Khatib
Investor Relations Contact:  Yousef Haj-Ahmad
Phone:  [phone]
E-mail: [e-mail]
Company URL: www.norgenbiotek.com

Product description:
   Norgen currently produces a variety of DNA molecular weight
markers ranging from 50 to 24,000 base pairs and are available in bulk
or ready-to-use formats. Norgen also produces its own recombinant
ribonucleases in bulk quantities. Norgen's services include Nucleic
Acid Purification, Adenovirus Vector Construction, and Custom Gene
Construction.

Company description:
   Norgen Biotek is an innovative company committed to providing
products and services to the multi-sectored biotechnology industry.
Established in 1998 to become the first biotechnology company in the
Niagara Region, it has since then developed technologies and products
for the purification of nucleic acids in both preparative and
industrial scales based on its patented technology.

Company:  NuGenesis Technologies Corporation

   NuGenesis(R) Technologies Corporation allows science-based
companies, which rely on electronic data, new opportunities to
generate competitive advantage, leverage innovation, create value and
comply with regulations. The company's role is to empower people with
products and services that free the data they generate from
proprietary application sources. This gives scientific professionals
the means for collaboration on a global scale, and allows managers
throughout the organization to make informed, timely decisions.
NuGenesis Technologies is founded on the principle that technology
should make data more accessible, so that scientists can use the
information they create to full advantage.


Company: OriGene Technologies, Inc.
Booth: 1117
Media Contact: Gillian F. Jay
Phone: [phone]
E-mail: [e-mail]
Company URL: www.origene.com

   Company description: OriGene is a high-throughput drug target
discovery and validation company with a focus on neoplastic,
degenerative and allergic disorders. Discovery is leveraged using its
proprietary experimental systems and patented gene cloning technology
platform. We have already filed patents on thousands of gene
sequences, many of which are related to breast cancer, prostate
cancer, angiogenesis, and are now seeking to establish research
alliances with pharmaceutical & biotech partners.

Company: Pharmagene Laboratories Limited
Booth: 2041
Media and Investor Relations Contact:  Melanie Toyne Sewel
Investor Relations Contact: Melanie Toyne Sewell
Phone:  [phone] or [phone]
Email: [e-mail]
Company URL: www.pharmagene.com

   Pharmagene generates value by working in partnership with
pharmaceutical and biotechnology companies to validate gene targets
and select those which are relevant to human disease. Utilising its
human tissue based approach, in combination with the most appropriate
technologies, Pharmagene provides information to support its partner's
drug discovery activities.

   Pharmagene's aim is to provide better drug discovery based on the
use of human biological information. Pharmagene focuses solely on the
use of fully consented human tissue for which it has established, and
maintains, one of the most effective tissue supply networks in the
world.

Company: Progen Industries Limited
Booth: 2100
Media and Investor Relations Contact:  Peter Devine
Phone: [phone]
E-mail: [e-mail]
Company URL: www.progen.com.au

Product description:
   Progen Industries Ltd is a contract manufacturer offering cGMP
fermentation and downstream processing. Progen also has an R&D program
developing inhibitors of heparanase and carbohydrate-protein
interactions. Progen's lead drug PI-88, a heparanase and angiogenesis
inhibitor, is in Phase II trials.

Company: Protein Sciences Corporation
Booth: 2630
Media Contact: Manon M.J. Cox
Investor Relations Contact: Daniel D. Adams
Phone: [phone]
E-mail: [e-mail]
Company URL: www.proteinsciences.com

Product description:
   Protein Sciences Corporation offers GeneXpress(R) , a protein
expression service. It sells proteins including HIV antigens (P24,
GP160, GP120, P66 and P55) to the research market. Check out our web
site for a complete product list. Also available is the patented high
yielding scaleable expresSF+(R) serum free insect cell line.

Company description:
   Protein Sciences Corporation is the world leader in making
proteins in insect cells using its proprietary baculovirus expression
vector system (BEVS) technology. The GeneXpress(R) program enables
rapid access to proteins (e.g. vaccines, therapeutics, antibodies,
multiple proteins in high through put fashion) for research purposes,
preclinical or clinical studies.


Company: Rubicon Genomics, Inc.
Booth: 2418
Media Contact: Julie Nagel
Investor Relations Contact: Thomas Collet
Phone: [phone]
E-mail: [e-mail]
Company URL: www.rubicongenomics.com

Product description:
   Rubicon's platform OmniPlex(TM) technology is a novel method for
preparation of genomic DNA into amplifiable units for subsequent
amplification and analysis in pharmacogenomic applications. Our
technology is applicable to both whole genome amplification and
molecular haplotyping to enable mass customization of genomics and
medicine in a highly efficient, cost-effective manner.


Company description:
   Rubicon Genomics is a development stage genomics company located
in Ann Arbor, Michigan. Rubicon is dedicated to developing and
commercializing tools that accelerate the pharmacogenomics revolution,
which will lead to high-throughput, genome-wide genetic analyses for
drug discovery and the development of more efficacious and safe drugs.

Company: Solutia Pharmaceutical Services Division
Booth: 2050 Pavilion D
Media Contact: Beth Rusert
Phone: [phone]
E-mail: [e-mail]
Investor Relations Contact: Liesl Livingston
Phone: [phone]
E-mail: [e-mail]
Company URL: www.solutia.com
Press Kit URL: www.solutia.com/corporate/pages/news/news_profile.asp

Product description:
   Solutia's Pharmaceutical Services Division provides integrated
drug development services from bench to market. These include a broad
range of chemistry services, clinical data management and drug
development consultancy. Science, speed and quality underpin the
company's commitment to its clients, which include many of the world's
leading pharmaceutical and biopharmaceutical companies.

Company description:
   Solutia uses world-class skills in applied chemistry to create
solutions for customers, whose products are used by consumers every
day. The company is a world leader in resins and additives;
performance products for laminated safety glass; pharmaceutical fine
chemicals; specialties like aviation fluids; and an integrated family
of nylon products.

Company: Swiss Pharma Contract
Booth: 435, in Pavilion Location Switzerland (428-437)
Media Contact: Riccardo Cervini
Investor Relations Contact: Rolf Pokorny
Phone: [phone]
E-mail: [e-mail]
Company URL: www. pharmacontract.ch

Product description:
Clinical Pharmacology
(Phase I, ADME, Bioequivalence Studies, Drug - Drug Interaction
Studies, Pharmacokinetic and Pharmacodynamic, Studies in Healthy
Subjects and Patients)
Clinical Research
(Phase II-to-IV, Anwendungsbeobachtungen)
Data Management, and Statistics Consulting

   Studies are conducted under GCP conditions and according to
international ICH guidelines.

Company description:
   Swiss Pharma Contract is a full-service clinical CRO (phases I-IV)
located in Basle, Switzerland. Our strength is based on our capacity
to greatly accelerate healthy subject studies and Proof of Concept
studies. Studies with healthy subjects are carried out in our own 24
beds phase I unit.

Company:  Windhover Information Inc.
Booth:  Booth 2120
Phone:  [phone]
E-mail:  [e-mail]
Company URL:  www.windhover.com

Product description:
   Publishers of In Vivo: The Business & Medicine Report, In Vivo
EuropeRx, Start-Up: Windhover's Review of Emerging Medical Ventures,
Strategic Intelligence Systems Databases and leading edge health care
industry conferences.

Company description:
   Since 1989 Windhover Information Inc. has been providing superior
analysis and commentary on health care business strategy, industry
deal making, marketplace and technology trends. Windhover's expertise
spans the pharmaceutical, biotech, med/device, supply/equipment and
diagnostics industries.

Note to media: Visit Business Wire at BIO 2002 in booth 2448.

To register for a free, custom news feed via Business Wire Press Pass, contact Business Wire Media Relations at [e-mail].